

**10/524716**  
**DT01 Rec'd PCT/PT 15 FEB 2005**

## CLAIMS

1. A method for modulating immuno-activity of a cell selected from a stimulator myeloid dendritic cell (DC) and a responder  $CD4^+CD8^-$  T cell or  $CD4^-CD8^+$  T cell said method comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 and in turn prevents, inhibits or otherwise down-regulates one or more functional activities of said cell by inducing cell lysis.
2. The method of claim 1 wherein the antibody is a monoclonal antibody or a functional equivalent thereof.
3. The method of claim 1 wherein the cell is mammalian derived.
4. The method of claim 3 wherein the mammalian cell is a human cell.
5. The method of claim 2 wherein the functional equivalent is an antigen-binding derivative, fragment, homolog, analog or chemical equivalent of the antibody.
6. The method of claim 1 wherein lysis is caused by antibody-dependent cell-mediated cytotoxicity.
7. The method of claim 2 wherein the antibody is conjugated with a toxic component which induces or otherwise facilitates lysis of the APC and/or lymphocyte.
8. A method for modulating the immuno-activity of a myeloid DC and/or T cell, said method comprising contacting said DC and/or T cell with an effective amount of a monoclonal antibody specific for CD83 for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate one or more of antigen endocytosis, antigen processing and/or antigen presentation by said DC and activation of macrophages, stimulation of antibody production, and/or killing of target cells by

- 47 -

said T cell.

9. A method for modulating an immune response in a subject, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or T cell's surface activation molecule for a time and under conditions sufficient to induce cell lysis of said DC and/or T cell.
10. A method for down-regulating the immuno-activity of an immuno-competent graft, said method comprising administering to said subject an effective amount of an antibody which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule, for a time and under conditions sufficient to induce cell lysis of said DC and/or a T cell.
11. A method for down-regulating the immuno-activity of a bone marrow graft in a subject, said method comprising administering to said subject an effective amount of monoclonal antibody against CD83, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate one or more functional activities of a DC and/or T-cell by inducing cell lysis.
12. A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft, said method comprising contacting said graft with an effective amount of an antibody or a derivative, homolog, analog, chemical equivalent or mimetic thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's surface activation CD83 molecule, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.
13. The method of claim 17 wherein the immuno-competent graft comprises allogenic bone marrow cells.

- 48 -

14. The method of claim 12 wherein the lymphocyte is a  $CD4^+ CD8^-$  or  $CD4^- CD8^+$  T cell.
15. A method for the prophylactic and/or therapeutic treatment of a condition characterized by the aberrant, unwanted or otherwise inappropriate immuno-activity of an immuno-competent graft in a subject, said method comprising contacting said graft with an effective amount of an antibody or a derivative, homolog, analog, chemical equivalent or mimetic thereof, which couples, binds or otherwise associates with a myeloid DC's and/or a T cell's CD83 molecule derived from said graft, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the said inappropriate immuno-activity of said graft by inducing cell lysis.
16. The method of claim 15 wherein the subject is a mammal.
17. The method of claim 16 wherein the mammal is a human.
18. The method of claim 15 wherein the condition is graft *versus* host disease.
19. The method of claim 15 wherein the graft is an allergenic bone marrow graft, spleen cell graft or stem cell graft.
20. A method for the prophylactic and/or therapeutic treatment of a condition characterized by an aberrant, unwanted or otherwise inappropriate immune response in a subject, said method comprising administering to said subject an effective amount of an antibody or antigen-binding fragment thereof which couples, binds or otherwise associates with CD83 on the surface of a myeloid DC's and/or a  $CD4^+ CD8^-$  T cell or  $CD4^- CD8^+$  T cell, for a time and under conditions sufficient to prevent, inhibit or otherwise down-regulate the immuno-activity of said DC and/or T cell by inducing cell lysis.

ART 34 AMDT  
RECEIVED